Back to Authors

Tilly, Hervé

0000-0001-7022-5246

Mayo Clinic

Department of Hematology and U1245, Centre Henri Becquerel, Rouen, France.

Citations 1

FLIPI24: A Modern Prognostic Model and Clinical Trial Enrichment Tool for Newly Diagnosed Follicular Lymphoma
Maurer, Matthew J. , Procházka, Vít , Flowers, Christopher R. , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot, Fournier, Marguerite , Larson, Melissa C. , Dietrich, Caroline E. , Ghesquières, Hervé , Gandhi, Maher K. , Cheah, Chan Y. , Hawkes, Eliza A. , Seymour, John F. , Freeman, Ciara L. , Friedberg, Jonathan W. , Casulo, Carla , Móciková, Heidi , Fürst, Tomáš, Feugier, Pierre, Tilly, Hervé , Davies, Andrew , Martin, Peter , Cohen, Jonathon B. , Lossos, Izidore S. , Smedby, Karin E. , Prochazka, Vit , Flowers, Christopher R , Villa, Diego , Bachy, Emmanuel , Cahn, Elliot J, Fournier, Marguerite , Larson, Melissa C , Dietrich, Caroline E , Kridel, Robert , Gandhi, Maher K , Cheah, Chan Yoon , Hawkes, Eliza , Seymour, John F , Clausen, Michael Roost , Casulo, Carla , Habermann, Thomas , Wang, Yucai , Nastoupil, Loretta J , de Nully Brown, Peter , Janikova, Andrea , Tilly, Hervé , Davies, Andrew , Cartron, Guillaume , Burack, W Richard , Chihara, Dai , Martin, Peter , Cohen, Jonathon B , Lossos, Izidore S , Kahl, Brad S , Sehn, Laurie H , E Smedby, Karin , Salles, Gilles A , Trnĕný, Marek , Link, Brian K , Morschhauser, Franck , Cerhan, James R , Maurer, Matthew , El‐Galaly, Tarec Christoffer , Jakobsen, Lasse Hjort , Clausen, Michael Roost , Wahlin, Björn , Casulo, Carla , Habermann, Thomas M. , Wang, Yucai , Nastoupil, Loretta J. , Brown, Peter de Nully , Belada, David , Feugier, Pierre , Haïoun, Corinne , Burack, Richard , Chihara, Dai , Kahl, Brad S. , Sehn, Laurie H. , Salles, Gilles , Trněný, Marek , Link, Brian K. , Morschhauser, Franck , Cerhan, James R.

Journal of Clinical Oncology | December 2, 2025 | Volume: 44 | Issue: 2 | Pages: 117-128

10.1200/jco-25-00892 Get It

PURPOSE Although most patients with follicular lymphoma (FL) can expect an indolent course, progressive lymphoma remains the primary cause of death during the first decade after diagnosis. Progression of disease within 24 months (POD24) of starting first-line (1L) immunochemotherapy defines a high-risk population with poor survival, but better risk stratification at diagnosis is needed. METHODS The FLIPI24 model was developed and internally validated to predict 24-month event rates using individual data from 4,485 patients treated with 1L immunochemotherapy from 10 observational cohorts of FL. Overall and cause-specific survival was further evaluated in FLIPI24 risk groups. External validation in the 1L immunochemotherapy setting was performed using the prospective observational Lymphoma Epidemiology of Outcomes (LEO) cohort (N = 565) and three randomized phase III trials (N = 3,192); extension to all patients with FL (any 1L therapy) was performed in the LEO cohort (N = 1,445) and its Molecular Epidemiology Resource subcohort (N = 1,074). RESULTS The FLIPI24 model uses age and four blood-based variables (hemoglobin, lactate dehydrogenase, beta-2 microglobulin, and WBC count). FLIPI24 showed consistent performance across validation and extension data sets, which was superior to existing prognostic tools. Across the four external immunochemotherapy validation data sets, patients with high-risk FLIPI24 (23%-32% of patients) had significantly higher 24-month event rates (22%-35%) and inferior 5-year overall survival (77%-83%) compared with patients with low-risk FLIPI24 (29%-31% of patients, 24-month event rates: 10%-12%; 5-year OS: 96%-97%). Results were consistent when evaluating lymphoma-related death and when extended to all patients with FL. CONCLUSION The FLIPI24 model robustly stratifies, at diagnosis, patients with FL at increased risk of lymphoma-related death versus patients with very low lymphoma-related mortality during the first decade after diagnosis. FLIPI24 can be used to enrich future clinical trial designs in newly diagnosed FL.